Literature DB >> 31123173

NME1 Drives Expansion of Melanoma Cells with Enhanced Tumor Growth and Metastatic Properties.

Ying Wang1, M Kathryn Leonard1, Devin E Snyder1, Matthew L Fisher1, Richard L Eckert1,2, David M Kaetzel3,2.   

Abstract

Melanoma is a lethal skin cancer prone to progression and metastasis, and resistant to therapy. Metastasis and therapy resistance of melanoma and other cancers are driven by tumor cell plasticity, largely via acquisition/loss of stem-like characteristics and transitions between epithelial and mesenchymal phenotypes (EMT/MET). NME1 is a metastasis suppressor gene that inhibits metastatic potential when its expression is enforced in melanoma and other cancers. Herein, we have unmasked a novel role for NME1 as a driver of melanoma growth distinct from its canonical function as a metastasis suppressor. NME1 promotes expansion of stem-like melanoma cells that exhibit elevated expression of stem cell markers (e.g., Sox2, Sox10, Oct-4, KLF4, and Ccnb-1), enhanced growth as melanoma spheres in culture, and enhanced tumor growth and lung colonizing activities in vivo. In contrast, NME1 expression did not affect the proliferation of melanoma cell lines in monolayer culture conditions. Silencing of NME1 expression resulted in a dramatic reduction in melanoma sphere size, and impaired tumor growth and metastatic activities of melanoma sphere cells when xenografted in immunocompromised mice. Individual cells within melanoma sphere cultures displayed a wide range of NME1 expression across multiple melanoma cell lines. Cell subpopulations with elevated NME1 expression were fast cycling and displayed enhanced expression of stem cell markers. IMPLICATIONS: Our findings suggest the current model of NME1 as a metastasis-suppressing factor requires refinement, bringing into consideration its heterogeneous expression within melanoma sphere cultures and its novel role in promoting the expansion and tumorigenicity of stem-like cells. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31123173      PMCID: PMC6677611          DOI: 10.1158/1541-7786.MCR-18-0019

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  28 in total

1.  Embryonic expression of nm23 during mouse organogenesis.

Authors:  M Lakso; P S Steeg; H Westphal
Journal:  Cell Growth Differ       Date:  1992-12

2.  nm23 influences proliferation and differentiation of PC12 cells in response to nerve growth factor.

Authors:  F Gervasi; I D'Agnano; S Vossio; G Zupi; A Sacchi; D Lombardi
Journal:  Cell Growth Differ       Date:  1996-12

3.  Dual functions of NME1 in suppression of cell motility and enhancement of genomic stability in melanoma.

Authors:  David M Kaetzel; Mary K Leonard; Gemma S Cook; Marian Novak; Stuart G Jarrett; Xiuwei Yang; Alexey M Belkin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-07-15       Impact factor: 3.000

4.  The in vitro spheroid melanoma cell culture assay: cues on tumor initiation?

Authors:  Tobias Schatton; Markus H Frank
Journal:  J Invest Dermatol       Date:  2010-07       Impact factor: 8.551

5.  Metastasis suppressor function of NM23-H1 requires its 3'-5' exonuclease activity.

Authors:  Qingbei Zhang; Joseph R McCorkle; Marian Novak; Mengmeng Yang; David M Kaetzel
Journal:  Int J Cancer       Date:  2011-01-01       Impact factor: 7.396

6.  Cancer stem cells: constantly evolving and functionally heterogeneous therapeutic targets.

Authors:  Tao Yang; Kiera Rycaj; Zhong-Min Liu; Dean G Tang
Journal:  Cancer Res       Date:  2014-04-08       Impact factor: 12.701

7.  Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth.

Authors:  Gianluca Civenni; Anne Walter; Nikita Kobert; Daniela Mihic-Probst; Marie Zipser; Benedetta Belloni; Burkhardt Seifert; Holger Moch; Reinhard Dummer; Maries van den Broek; Lukas Sommer
Journal:  Cancer Res       Date:  2011-03-10       Impact factor: 12.701

8.  Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity.

Authors:  A Leone; U Flatow; K VanHoutte; P S Steeg
Journal:  Oncogene       Date:  1993-09       Impact factor: 9.867

Review 9.  Learning therapeutic lessons from metastasis suppressor proteins.

Authors:  Steven Christopher Smith; Dan Theodorescu
Journal:  Nat Rev Cancer       Date:  2009-02-26       Impact factor: 60.716

10.  Diva/BclB regulates differentiation by inhibiting NDPKB/Nm23H2-mediated neuronal differentiation in PC-12 cells.

Authors:  Jasmin Qian Ru Lim; Jia Lu; Bei Ping He
Journal:  BMC Neurosci       Date:  2012-10-11       Impact factor: 3.288

View more
  10 in total

Review 1.  Heterogeneity in Melanoma.

Authors:  Mei Fong Ng; Jacinta L Simmons; Glen M Boyle
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

2.  Long Noncoding RNA LINC00261 Reduces Proliferation and Migration of Breast Cancer Cells via the NME1-EMT Pathway.

Authors:  Guangxiu Guo; Sujuan Dai; Qing Chen
Journal:  Cancer Manag Res       Date:  2020-05-04       Impact factor: 3.989

3.  A rare subpopulation of melanoma cells with low expression of metastasis suppressor NME1 is highly metastatic in vivo.

Authors:  Devin Snyder; Ying Wang; David M Kaetzel
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

4.  Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures.

Authors:  Guohong Gao; Zhilong Yu; Xiaoyan Zhao; Xinyi Fu; Shengsheng Liu; Shan Liang; Aijun Deng
Journal:  Sci Rep       Date:  2021-11-15       Impact factor: 4.379

5.  Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.

Authors:  Martina Radić; Ignacija Vlašić; Maja Jazvinšćak Jembrek; Anđela Horvat; Ana Tadijan; Maja Sabol; Marko Dužević; Maja Herak Bosnar; Neda Slade
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

6.  Metabolic remodeling of pyrimidine synthesis pathway and serine synthesis pathway in human glioblastoma.

Authors:  Akira Nakamizo; Yuichiro Miyamatsu; Haruka Hirose; Toshiyuki Amano; Satoshi Matsuo; Minako Fujiwara; Teppei Shimamura; Koji Yoshimoto
Journal:  Sci Rep       Date:  2022-09-29       Impact factor: 4.996

7.  Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis.

Authors:  Ainhoa Lapitz; Ander Arbelaiz; Colm J O'Rourke; Jose L Lavin; Adelaida La Casta; Cesar Ibarra; Juan P Jimeno; Alvaro Santos-Laso; Laura Izquierdo-Sanchez; Marcin Krawczyk; Maria J Perugorria; Raul Jimenez-Aguero; Alberto Sanchez-Campos; Ioana Riaño; Esperanza Gónzalez; Frank Lammert; Marco Marzioni; Rocio I R Macias; Jose J G Marin; Tom H Karlsen; Luis Bujanda; Juan M Falcón-Pérez; Jesper B Andersen; Ana M Aransay; Pedro M Rodrigues; Jesus M Banales
Journal:  Cells       Date:  2020-03-14       Impact factor: 6.600

8.  Bioinformatic Analysis Identifies Potential Key Genes in the Pathogenesis of Melanoma.

Authors:  Yanjie Han; Xinxin Li; Jiliang Yan; Chunyan Ma; Xin Wang; Hong Pan; Xiaoli Zheng; Zhen Zhang; Biao Gao; Xin-Ying Ji
Journal:  Front Oncol       Date:  2020-10-16       Impact factor: 6.244

9.  Comprehensive analysis of the NME gene family functions in breast cancer.

Authors:  Haoming Wu; Xinjian Huang; Siliang Chen; Siqi Li; Jikun Feng; Xiazi Zouxu; Zeming Xie; Xinhua Xie; Xi Wang
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

10.  Enrichment of Melanoma Stem-Like Cells via Sphere Assays.

Authors:  Nabanita Mukherjee; Karoline A Lambert; David A Norris; Yiqun G Shellman
Journal:  Methods Mol Biol       Date:  2021
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.